Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CBLB | Q13191 | 1/20 | 0.37 |
| ▸ | JAK2 | O60674 | 1/20 | 0.33 |
| ▸ | JAK1 | P23458 | 1/20 | 0.33 |
| ▸ | TYK2 | P29597 | 1/20 | 0.33 |
| ▸ | JAK3 | P52333 | 1/20 | 0.33 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.33 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.33 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.33 |
| ▸ | VSIR | Q9H7M9 | 10/20 | 0.32 |
| ▸ | PDCD1 | Q15116 | 8/20 | 0.32 |
| ▸ | CD274 | Q9NZQ7 | 8/20 | 0.32 |
| ▸ | MAP4K4 | O95819 | 2/20 | 0.32 |
| ▸ | ABL1 | P00519 | 1/20 | 0.31 |
| ▸ | HPSE | Q9Y251 | 1/20 | 0.31 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.31 |
| ▸ | RAF1 | P04049 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24820525 | 1.00 | CBLB (0.37) | CBLBJAK2JAK1TYK2JAK3 | |
| SCHEMBL24821816 | 0.92 | CBLB (0.36) | CBLBVSIRPDCD1CD274S1PR1 | |
| SCHEMBL30152704 | 0.92 | CBLB (0.36) | CBLBVSIRPDCD1CD274S1PR1 | |
| SCHEMBL24818776 | 0.90 | S1PR1 (0.33) | CBLBPDCD1CD274HPSES1PR1 | |
| SCHEMBL30152554 | 0.90 | CBLB (0.40) | CBLBVSIRPDCD1CD274 | |
| SCHEMBL30153135 | 0.90 | CBLB (0.42) | CBLBVSIRPDCD1CD274 | |
| SCHEMBL24819947 | 0.90 | CBLB (0.40) | CBLBVSIRPDCD1CD274 | |
| SCHEMBL24819946 | 0.90 | CBLB (0.42) | CBLBVSIRPDCD1CD274 | |
| SCHEMBL30153243 | 0.88 | CBLB (0.34) | CBLBCD274 | |
| SCHEMBL24821767 | 0.87 | CBLB (0.46) | CBLBJAK2JAK1TYK2JAK3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250163038-A1 | CBL-B MODULATORS AND USES THEREOF | NIMBUS CLIO, INC. | 2025-05-22 | — | — | US | disclosed |
| EP-4359381-A1 | CBL-B MODULATORS AND USES THEREOF | Nimbus Clio, Inc. (US) | 2024-05-01 | — | — | EP | disclosed |
| WO-2022272248-A1 | CBL-B MODULATORS AND USES THEREOF | NIMBUS CLIO, INC. (US) | 2022-12-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250163038-A1 | CBL-B MODULATORS AND USES THEREOF | CBLB, CBL, CBLC | CBLB 1/4885JAK2 937/4885JAK1 448/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.